NCT00003011 is a Phase 3 clinical trial of marimastat in Lung Cancer, sponsored by NCIC Clinical Trials Group.

Who is sponsoring NCT00003011?

NCT00003011 is sponsored by NCIC Clinical Trials Group.

What drugs are being tested in NCT00003011?

Interventions in NCT00003011: marimastat, Placebo.

What condition does NCT00003011 study?

NCT00003011 studies Lung Cancer.

Is NCT00003011 still recruiting?

NCT00003011 is currently completed. Last updated 3 April 2020.

Last reviewed 2020-04-03 · How we verify

NCT00003011

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer

Completed Phase 3 Last updated 3 April 2020

What this trial tests

Phase 3 trial testing marimastat in Lung Cancer in 555 participants. Completed in 15 December 2008.

Timeline

31 January 1997

Primary endpoint
13 February 2001

15 December 2008

Quick facts

Lead sponsor	NCIC Clinical Trials Group
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	555
Start date	31 January 1997
Primary completion	13 February 2001
Estimated completion	15 December 2008
Sites	38 locations across Canada

Drugs / interventions tested

marimastat — full drug profile →
Placebo

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

NCIC Clinical Trials Group

Who can join

Adults 16 to 120, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Marimastat may stop the growth of lung cancer by stopping blood flow to the tumor. It is not yet known if marimastat is an effective treatment for small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of marimastat with a placebo following chemotherapy in treating patients who have small cell lung cancer.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor biomarkers for diagnosis, prognosis and targeted therapy.
Zhou Y, Tao L, Qiu J, Xu J, et al · · 2024 · cited 379× · PMID 38763973 · DOI 10.1038/s41392-024-01823-2
Tumor stroma as targets for cancer therapy.
Zhang J, Liu J. · · 2013 · cited 139× · PMID 23064233 · DOI 10.1016/j.pharmthera.2012.10.003
Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer.
Zhang M, Zhang B. · · 2025 · cited 69× · PMID 40211368 · DOI 10.1186/s40164-025-00647-2
Immunomodulatory roles of metalloproteinases in rheumatoid arthritis.
Bian Y, Xiang Z, Wang Y, Ren Q, et al · · 2023 · cited 45× · PMID 38035026 · DOI 10.3389/fphar.2023.1285455
Advancing Treatment of Bone Metastases through Novel Translational Approaches Targeting the Bone Microenvironment.
Sethakorn N, Heninger E, Sánchez-de-Diego C, Ding AB, et al · · 2022 · cited 27× · PMID 35159026 · DOI 10.3390/cancers14030757
Proteases Regulate Cancer Stem Cell Properties and Remodel Their Microenvironment.
Habič A, Novak M, Majc B, Lah Turnšek T, et al · · 2021 · cited 11× · PMID 34310223 · DOI 10.1369/00221554211035192
Combined Radiochemotherapy: Metalloproteinases Revisited.
Waller V, Pruschy M. · · 2021 · cited 10× · PMID 34055644 · DOI 10.3389/fonc.2021.676583

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other NCIC Clinical Trials Group trials

Trials by the same sponsor.

NCT01916187 — Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma · Phase 1 · withdrawn
NCT01830621 — BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma · Phase 3 · completed
NCT01652144 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma · Phase 2 · completed
NCT01627054 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia · Phase 2 · completed
NCT01486368 — A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00003011 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NCIC Clinical Trials Group
Last refreshed: 3 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00003011.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing